Final analysis of OLE study of Fintepla in LGS

Belgium’s largest drugmaker UCB (Euronext: UCB) has announced the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS), which was published in Epilepsy and Behavior.

Children and adults aged 2-35 years treated with fenfluramine showed a significant sustained reduction in frequency of seizures associated with a fall (drop seizures) from Month 2 of OLE to end of study compared with baseline and an improvement in global functioning reported by caregivers and investigators. No new or unexpected treatment-emergent adverse events (TEAEs) were reported.

Parents/caregivers reported improvements in social interactions and activities, feelings of stigma, general health, quality of life, and their own anxiety. These results follow final analysis of OLE study evaluating safety and effectiveness of fenfluramine in Dravet Syndrome earlier this year, showing sustained reduction in monthly convulsive seizure frequency and long-term tolerability.